The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils - Blatt, Katharina; Herrmann, Harald; Mirkina, Irina; Hadzijusufovic, Emir; Peter, Barbara; Strommer, Sabine; Hoermann, Gregor; Mayerhofer, Matthias; Hoetzenecker, Konrad; Klepetko, Walter; Ghanim, Viviane; Marth, Katharina; et al. (PloS one, 2012)
Keywords: 1-Phosphatidylinositol 3-kinase; Adult; Aged; Aged, 80 and over; Allergens; Allergies; Animals; Antibody-Dependent Cell Cytotoxicity - drug effects; Apoptosis; Basophils - drug effects; Basophils - immunology; Biology; Boltzmann, Ludwig Eduard (1844-1906); Bone marrow; Cancer; CD63 antigen; Cell activation; Cell Line, Tumor; Cell Proliferation - drug effects; Down-Regulation - drug effects; Drug dosages; Female; Growth; Hematology; Histamine; Humans; Imidazoles - adverse effects; Imidazoles - pharmacology; Immunoglobulin E; Immunoglobulin E - immunology; Immunoglobulin E - metabolism; Immunoglobulin E - pharmacology; Immunoglobulin E - physiology; Immunology; Infectious diseases; Internal medicine; Kinases; Laboratories; Leukemia; Leukocytes (basophilic); Ligands; Male; Mast cells; Mast Cells - drug effects; Mast Cells - immunology; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy - adverse effects; Oncology; Pharmacology; Phosphoinositide-3 Kinase Inhibitors; Quinolines - adverse effects; Quinolines - pharmacology; Rapamycin; Signal transduction; Signaling; Stem cells; Thoracic surgery; Thymidine; TOR protein; TOR Serine-Threonine Kinases - antagonists & inhibitors; Veterinary medicine; Xenograft Model Antitumor Assays; Xenografts